Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports
Investing.com — Here is your Pro Recap of 5 head-turning deal dispatches you may have missed last week: deals at Bristol Myers Squibb/Mirati Therapeutics, Eli Lilly/Point Biopharma, Suncor Energy/TotalEnergies, deal talks at Exxon Mobil/Pioneer Natural Resources, and potential sale of EngageSmart.
Pioneer shares were recently up another 1.7% in premarket trading Monday. Exxon shares were climbing 2.5%.) said it had agreed to buy the cancer biotech for around $1.4 billion. Under the terms of the deal, Lilly is offering $12.50 per Point Biopharma share held. Both Point and Lilly expect the deal to close by the end of the year.) Canada operations - TotalEnergies EP Canada Ltd - which holds a 31.23% working interest in the Fort Hills oil sands mining project, for C$1.468 billion.
Upon closing of the transaction, Suncor will own 100% of Fort Hills, which along with its 100% ownership of Firebag and MacKay River in-situ assets, enhances Suncor's access to long-life, physically-integrated bitumen supply, maximizing the utilization of its wholly-owned Base Plant upgraders post the end of the Base Mine life.), per Reuters. Investment banks Goldman Sachs Group and Evercore are working with EngageSmart on a sale process, which is in its early stages.
According to the report, no definitive deal has been confirmed, and General Atlantic, which holds a 54% stake in EngageSmart, may opt for a gradual sell-down of its stake on the stock market instead.We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion dealBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Read more »
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Read more »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Read more »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Read more »
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 BillionThe acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb’s best-selling products.
Read more »
Shares in weapons makers Lockheed Martin, RTX surge following surprise attack on Israel and other stocks on the moveShares in RTX, Lockheed Martin, Marathon Oil, Occidental Petroleum, Mirati Therapeutics, and Bristol Myers Squibb Co. were on the move
Read more »